About Very large A-kinase anchor protein
Very large A-kinase anchor protein (CRYBG3) is a protein
from Homo sapiens identified by UniProt accession
Q68DQ2, 2970 residues long.
MolForge cross-references it against 0 known binders and
15 disease associations.
Target properties
| Protein name | Very large A-kinase anchor protein |
|---|
| UniProt accession | Q68DQ2 |
|---|
| Gene | CRYBG3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 2970 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (15)
Diseases linked to this target (Open Targets).
- vitamin supplement exposure measurement · score 0.29
- Bardet-Biedl syndrome · score 0.26
- protein measurement · score 0.21
- neoplasm · score 0.06
- non-small cell lung carcinoma · score 0.03
- urate measurement · score 0.02
- heel bone mineral density · score 0.02
- cancer · score 0.01
- insulin resistance · score 0.01
- invasive breast ductal carcinoma · score 0.01
3D Structure (9)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (2970 residues)
MSSGRRRGSA PWHSFSRFFA PRSPSRDKEE EEEERPGTSP PPAPGRSAAS VENEPMSTSQ KKENVLSSEA VKIRQSEDKR NHAEKPVTLP VQEDPKKAYD LSSSTSDTKI GESDRQPKES FFQFLGNLFN ISGKSSLGEA KQSSFKDDQD KTEKDLQNPS DHHEDGIKRE REIFSGSLRT QTHPTEEQDS NSSELSDAFS LDTTQDSDQE TTNLLKQIDG KPEKPSVTYA TYRGPRHIGK YLKQQTGLAT VNTLDRENES SDSSTNRHID PGSEIEAGVL PLLLSASTDS SMKGNLLEGP LEDSDCSKTS FNKENSLTNN PELQNIASSN NLLNKNAWGS IERNRSSPSS VTNSSYDGES DSQHHLSCEP VSQTNRNLVC SALLTGSNHR KVPCSPDFQR VTTTENTIKE NSTVMSNRTL VQREELVEPQ GPAISDFSCS KSDGSDTTEQ ESTNLPSPNK SIRHEHLQLP ESECSDKQTI DSSSKQAATH TNIIALQRHA VTDTEFVNEG KRLSAQDSQK NVAVREIRRE TESASAGESI ASSHVKAPED KIESLPKDTD QYFETKAKKL DFRSHDKIPH IRMNKKDLAS LNYISESAVV ASLGNENAPE LKFELNRSHI SETPLDSESP QQAEVSPDAK TSLSLDCKKL NFSISPPTFV SGVGMLSKLD IPDLMNEGSP VPIETGNVNI VGISYQPRKC KEENVKNHVE AAGRKSPPPS FCLEYTSAIF EFKEVLSNSE KCQVLPGSEA SGPHLTGLEL LSFDSGNLSK DCSSILSQDP NRVELVSSNT KANMSIIEKS DSLSLEAKTA NIVSKAEIDG QNNVLVESHS GRGKTISLSK VSLSKVEPRN ISQDKMSSFP LKITHVPEKP ILSELTFLEV EQGKRFQSIN HNEIGEKCSD AGLKENCQAE LSPAASKYED KPEPEVDALG SPPALLKSNI SWILPPIHDE KISRQMAQNC EAHTCVFHQS LDICGTKKIS GHSEMAELSL TNISPKFQET GSMKVNSPFL DSDSSLEKNS SASEDSSFLK VPSVLKLEKK SSSYRKKENI HFLNGGIDSV SSSSSYPEEV SMIVNSHKPQ NNLDSIQVTK DLTHEGTSVT NLLYPTTSYL EFETSVSIGT EVTPFQEHFG IYTGKISIDF PTAAQFDNLV EAETGAVAGP AASVNSSGQQ CSEASAEHIE ARRRAHDQLL DLKSSLLKKA DTLIGEIFNS VREELKFKHT VSTCQEHIAI EGIMNLGTLK EDISEKNPSE VTLTEIQQTE GLEEQGMENM SEVKEKPCVS PTVGEKNLLV DPNSMNVSCL LEDKARELVN EIIYVAQEKL RNDTFEDTED TWDSELQANT SKILNSDSVK PHDVVREFLV SEQPVNQSTQ ISENKVLNEF FSLSNLASGT ESIKGGEIVL YQKSLFSGNG SGLSDSINLQ ESDTVLLAED MSHKRLDDRV KTHLFRSEDC NETMEIENVD NNKTETEDRR TLVLNFKWPP LVNDDIHAPG TSKSSLSDSL VCISEKNLPG HSKNTPLAMS DVGKVHKKDN EINIGKIELI PSMLETGKTN KKDAELNILK YEAVPPMIEM GRIHKMDAEL NVTKTEPKAN VFKMGEVYQM DAESCIEKTE GSAVILGMEK AYKMKDTEGD IGKIEVIPMM PEVKNIHQKD AEGDIVKTEM TPVTVDMENI YQTHAEGDIG KTGTIALSEV ENIHQKGGEG ISEKAEVIPV TLAMENTYQK DAEGDIGKAE VMPVRLEMEN TYPKDTERDG GKTEVMPLAL EVVNTYQKNA KGFTGNTEGS VLKMEATYRK TAEEVIKNTE IVPCVLKVKE AHETAPAPLE MEKACKRDVK ETIGATVSTP SVIEMEKISP EDRGENIGKH KVLPAVVDIE KIHGTGLELT TKQGEAMLPA FESKTPQEYA EGSVEETKEE PTEIKEGLIA HENRLPTYFR GYESPTLSKD YEGYPAPAMP DFQPGDTTVR LDKRMSLTAI YDKRRETDYS DKGYNLAFVS QDEQENSSFT ILYEEPLQEE DKYASAEARQ TQSVLFHDTS ADSMPVLACE RSESRTDLVH HFEKGTKLGE TFDSDSSEMF LSVEAKRYKI YPLALSPIYE DDSSQEDILS SEVSPGHHGP RKSRDSENQS SSVLSLLQSV SERLKMNFDE DDREAADEEE EEEEAAVLHK GDLRAGSGER VTFQLPDPSI TFYPDDQESV GISKNSYVMP NEPTTSNLQV GLWPEKTSFL QKSDLTSKLH SSLKSAYHQY LQTSQSHSSE KGARFGGIFQ EPVSKYFRVQ DSPGRLSPFI ENVDKQTLRC NPRPGKMVIY DLHESTYKQE VYCNIPDATS WSFPNGVLIK VVRGCWILYE KPHFRGQKCV LEEGEKVLNR DWILQNRRHP QRNFILGSLK RVLKDCSIPE IELFPQSDPA CCPVYIQRAV PNLEELNISK SVSFTVKSGV WLAYPDINFK GQATVLEEDH GLFEISTAEM KSLHPLQMGG LKVEMPMNLK VIIYEKPHFH GQAKEFSEHI DSVPNFLKNN GDFHRIGSIR VIGGVWVAYE KEHFKGQQFL LEEGDFEDSN ACGALSSPIL SFRYLQANFI ESSVTLFESD LESGKFIDIT NQEISDLEEI GFGSKTRSIH VKSGVWVAYQ QKFFCGEQYI LEKGKYKCFF DWGGSNNIIM SIRPIQLEPL GINEPPHLLK AFSKPGFQGE CIDFTEETSD LTSLMPCSFK VLRGCWLLYY QEDMFVNHCV LEEGLYADLT SCGCPASKVK SLKPIDYVFE EPSISLFALE HCEGRELHLE EAVNSVLNKD LHFYTQSVWV KSGLWIAYEG SNFLGRQILL RPNEIPNWTA FSRWKTIGSL RPMKQPAVYI RIKNRAQGEY LTVTGSLADT RATSVCISPY SGKNTQIWYY CRGLFKSKAS DTCLDVIGGR DTPGAKVALW TEHGQFRQKW RLNKNGTISS YLSDQLVLDV KGGNYCDKTH VIVNQPLEGE ETQKWDIEIL
Explore Very large A-kinase anchor protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets